Results 101 to 110 of about 3,096 (189)

Evolving Therapeutic Paradigms in Bladder Cancer: the Impact of Immunotherapy and Antibody-Drug Conjugates [PDF]

Bladder cancer is a significant global health challenge. Despite advances in surgery and platinum-based chemotherapy over the decades, limited improvements in clinical outcomes have been observed.
Ahmed Attia Ahmed Abdelmoaty, Ahmed Helmy Abdelhaseb, Shahd Mustafa Ibrahim   +2 more
core   +1 more source

Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside [PDF]

, 2022
Audisio, A., Buttigliero, C., Delcuratolo, M. D., Di Maio, M., Pisano, C., Scagliotti, G. V., Tucci, M., Turco, F., Ungaro, A.   +8 more
core   +1 more source

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium

Current Oncology
Enfortumab vedotin (EV) in combination with pembrolizumab (P) has led to a new paradigm for the treatment of metastatic urothelial carcinoma (mUC). Since the presentation of the results of the EV-302 trial at the European Society of Medical Oncology 2023
Catherine C. Fahey, Sean Clark-Garvey, Sima Porten, Ashish M. Kamat, Thomas W. Flaig, John A. Taylor, William Y. Kim, Matthew I. Milowsky   +7 more
doaj   +1 more source

Efficacy and safety of antibody-drug conjugates in the treatment of advanced urological cancers: a systematic review and a meta-analysis

Frontiers in Pharmacology
BackgroundAntibody-drug conjugates (ADCs) offer novel therapeutic options for advanced urological cancers, but their efficacy and safety vary across cancer types.
Tian Liu, Xiao Xie, Yangz-Zi Ren, Zongyu Li, Maoping Cai, Yuzhong Yu, Lin Zhuo   +6 more
doaj   +1 more source

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation [PDF]

The introduction of enfortumab vedotin combined with pembrolizumab (EV-P) as a first-line treatment for advanced urothelial carcinoma (UC) has transformed the therapeutic landscape and holds great promise for improving patient outcomes.
Andrea Gallina, Andrea Gallina, Chiara Maria Agrippina Clerici, Fabio Monni, Fabio Turco, Giovanna Pecoraro, Giovanna Pecoraro, Giovanna Pecoraro, Giuseppe Salfi, Giuseppe Salfi, Ilaria Colombo, Jessica Barizzi, Luigi Tortola, Marialuisa Puglisi, Marialuisa Puglisi, Martino Pedrani, Milo Frattini, Nicola Fossati, Nicola Fossati, Ricardo Pereira Mestre, Ricardo Pereira Mestre, Ricardo Pereira Mestre, Rossella Graffeo, Silke Gillessen, Silke Gillessen, Stefania Rizzo, Stefania Rizzo, Ursula Vogl   +27 more
core   +1 more source

Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules

Frontiers in Molecular Medicine
The classical cadherin (CDH), claudin (CLDN) and nectin families of transmembrane-type adhesion molecules are located at adherens or tight junctions in epithelial cells but diffuse to the nonjunctional cell surface in solid tumors with epithelial ...
Masuko Katoh, Yohann Loriot, Yohann Loriot, Izuma Nakayama, Akinobu Hamada, Akinobu Hamada, Kohei Shitara, Masaru Katoh, Masaru Katoh, Masaru Katoh   +9 more
doaj   +1 more source

Comprehensive Overview on Antibody Drug Conjugates- A Promising Approach in Cancer Therapy [PDF]

Chemotherapy remains a cornerstone in cancer treatment, utilizing cytotoxic agents to kill or inhibit the growth of cancer cells. However, its efficacy is often limited by systemic toxicity and the development of resistance.
Jinnah, Aadhira, Muppa, Lenna, Ravindranathan, Shruthi, Shibu, Achsa Sharon, Sivaram, S   +4 more
core   +2 more sources

Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract [PDF]

Urothelial carcinoma of the upper urinary tract (UTUC) presents a significant clinical challenge, often requiring aggressive surgical intervention for optimal management.
Al Shaarani, Majd, Cen, Putao, Chan, Kok Hoe, Shu, Tung   +3 more
core   +1 more source

Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer:comparison between patients from a Dutch nationwide cohort and KEYNOTE-045 [PDF]

Background and objective: Pending adoption of enfortumab-vedotin plus pembrolizumab in first-line setting, platinum-based chemotherapy remains the standard of care for patients with metastatic or locally advanced urothelial cancer (mUC).
Aben, Katja, Franken, Mira, Mehra, Niven, Richters, Anke, Rikhof, Bart, Robbrecht, Debbie, Suelmann, Britt, Westgeest, Hans   +7 more
core   +1 more source

Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin: Single-Center Case Series

Annals of Internal Medicine: Clinical Cases
Enfortumab vedotin (EV) revolutionized management of metastatic urothelial carcinoma. Multiple-organ dysfunction is a rare adverse event associated with EV with unknown mechanisms.
Mohammad Jad Moussa, Nathaniel R. Wilson, Anindita Ghosh, Meenakshi B. Bhattacharjee, Jonathan L. Curry, Woo Cheal Cho, Anisha B. Patel, Mouhammed Amir Habra, Sonali N. Thosani, Matthew T. Campbell, Arlene O. Siefker-Radtke, Omar Alhalabi, Nupur J. Kikani   +12 more
doaj   +1 more source